Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:PD173074
go back to main search page
Accession:CHEBI:63448 term browser browse the term
Definition:A member of the class of ureas that is 1-tert-butylurea in which one of the hydrogens attached to N(3) is substituted by a pyrido[2,3-d]pyrimidin-7-yl group, which is itself substituted at positions 2 and 6 by a 4-(diethylamino)butyl]amino group and a 3,5-dimethoxyphenyl group, respectively. It is a FGF/VEGF receptor tyrosine kinase inhibitor.
Synonyms:exact_synonym: 1-tert-butyl-3-[2-{[4-(diethylamino)butyl]amino}-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]urea
 related_synonym: Formula=C28H41N7O3;   InChI=1S/C28H41N7O3/c1-8-35(9-2)13-11-10-12-29-26-30-18-20-16-23(19-14-21(37-6)17-22(15-19)38-7)25(31-24(20)32-26)33-27(36)34-28(3,4)5/h14-18H,8-13H2,1-7H3,(H3,29,30,31,32,33,34,36);   InChIKey=DXCUKNQANPLTEJ-UHFFFAOYSA-N;   PD 173074;   SMILES=CCN(CC)CCCCNc1ncc2cc(-c3cc(OC)cc(OC)c3)c(NC(=O)NC(C)(C)C)nc2n1
 alt_id: MESH:C115711
 xref: CAS:219580-11-7;   LINCS:LSM-1026
 xref_mesh: MESH:C115711
 xref: PMID:14598292;   PMID:14715624;   PMID:14960493;   PMID:16448042;   PMID:17356708;   PMID:19340397;   PMID:19903855;   PMID:19955487;   Reaxys:10130688



show annotations for term's descendants           Sort by:
PD173074 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Birc5 baculoviral IAP repeat-containing 5 multiple interactions ISO [arsenic trioxide results in increased susceptibility to PD 173074] which results in decreased expression of BIRC5 protein CTD PMID:27794399 NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
JBrowse link
G Ccnd1 cyclin D1 multiple interactions ISO [PKI 166 co-treated with PD 173074] results in decreased expression of CCND1 protein CTD PMID:15377668 NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
JBrowse link
G Fgf1 fibroblast growth factor 1 multiple interactions ISO PD 173074 inhibits the reaction [FGF1 protein results in increased phosphorylation of FGFR4 protein] CTD PMID:15709206 NCBI chr18:30,686,555...30,772,667
Ensembl chr18:30,686,581...30,772,357
JBrowse link
G Fgfr1 Fibroblast growth factor receptor 1 decreases activity
multiple interactions
decreases expression
ISO PD 173074 results in decreased activity of FGFR1 protein
[PD 173074 results in decreased activity of FGFR1 protein] inhibits the reaction [[Crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein]; Arsenic Trioxide promotes the reaction [PD 173074 results in decreased expression of FGFR1 protein]; PD 173074 promotes the reaction [Arsenic Trioxide results in decreased expression of FGFR1 protein]
CTD PMID:22683780 PMID:27794399 NCBI chr16:66,491,930...66,547,161
Ensembl chr16:66,494,042...66,547,350
JBrowse link
G Fgfr3 fibroblast growth factor receptor 3 decreases activity ISO PD 173074 results in decreased activity of FGFR3 protein CTD PMID:15029211 NCBI chr14:76,987,242...77,002,671
Ensembl chr14:76,987,993...77,003,341
JBrowse link
G Fgfr4 fibroblast growth factor receptor 4 multiple interactions
decreases activity
ISO PD 173074 inhibits the reaction [FGF1 protein results in increased phosphorylation of FGFR4 protein]
PD 173074 results in decreased activity of FGFR4 protein
CTD PMID:15377668 PMID:15709206 NCBI chr17:9,461,541...9,476,268
Ensembl chr17:9,461,547...9,476,242
JBrowse link
G Hgf hepatocyte growth factor multiple interactions ISO [PD 173074 results in decreased activity of FGFR1 protein] inhibits the reaction [[crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein] CTD PMID:22683780 NCBI chr 4:18,673,736...18,745,582
Ensembl chr 4:18,677,101...18,745,409
JBrowse link
G Mapk1 mitogen activated protein kinase 1 decreases phosphorylation
multiple interactions
decreases expression
ISO PD 173074 results in decreased phosphorylation of MAPK1 protein
PD 173074 inhibits the reaction [PHLPP1 gene mutant form results in increased phosphorylation of MAPK1 protein]
PD 173074 results in decreased expression of MAPK1 protein
CTD PMID:15029211 PMID:25953896 PMID:27794399 NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
JBrowse link
G Mapk3 mitogen activated protein kinase 3 decreases phosphorylation
multiple interactions
decreases expression
ISO PD 173074 results in decreased phosphorylation of MAPK3 protein
PD 173074 inhibits the reaction [PHLPP1 gene mutant form results in increased phosphorylation of MAPK3 protein]
PD 173074 results in decreased expression of MAPK3 protein
CTD PMID:15029211 PMID:25953896 PMID:27794399 NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
JBrowse link
G Met MET proto-oncogene, receptor tyrosine kinase multiple interactions ISO [PD 173074 results in decreased activity of FGFR1 protein] inhibits the reaction [[crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein] CTD PMID:22683780 NCBI chr 4:45,790,456...45,898,139
Ensembl chr 4:45,790,791...45,897,876
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions ISO [arsenic trioxide co-treated with PD 173074] results in increased expression of PARP1 protein modified form; [arsenic trioxide results in increased susceptibility to PD 173074] which results in increased expression of PARP1 protein modified form; [PD 173074 results in increased susceptibility to arsenic trioxide] which results in increased expression of PARP1 protein modified form CTD PMID:27794399 NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
JBrowse link
G Phlpp1 PH domain and leucine rich repeat protein phosphatase 1 multiple interactions ISO PD 173074 inhibits the reaction [PHLPP1 gene mutant form results in increased phosphorylation of MAPK1 protein]; PD 173074 inhibits the reaction [PHLPP1 gene mutant form results in increased phosphorylation of MAPK3 protein] CTD PMID:25953896 NCBI chr13:22,308,532...22,530,978
Ensembl chr13:22,308,548...22,530,977
JBrowse link
G Raf1 Raf-1 proto-oncogene, serine/threonine kinase decreases expression
multiple interactions
ISO PD 173074 results in decreased expression of RAF1 protein; PD 173074 results in decreased expression of RAF1 protein modified form
[arsenic trioxide co-treated with PD 173074] results in decreased expression of RAF1 protein; [arsenic trioxide co-treated with PD 173074] results in decreased expression of RAF1 protein modified form; [arsenic trioxide results in increased susceptibility to PD 173074] which results in decreased expression of RAF1 protein; [PD 173074 results in increased susceptibility to arsenic trioxide] which results in decreased expression of RAF1 protein; [PD 173074 results in increased susceptibility to arsenic trioxide] which results in decreased expression of RAF1 protein modified form; arsenic trioxide promotes the reaction [PD 173074 results in decreased expression of RAF1 protein modified form]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[arsenic trioxide co-treated with PD 173074] results in decreased expression of RAF1 protein modified form]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[arsenic trioxide co-treated with PD 173074] results in decreased expression of RAF1 protein]
CTD PMID:27794399 NCBI chr 4:148,679,534...148,740,265
Ensembl chr 4:148,679,530...148,740,317
JBrowse link
G Rps6kb1 ribosomal protein S6 kinase B1 multiple interactions ISO [PKI 166 co-treated with PD 173074] results in decreased activity of RPS6KB1 protein CTD PMID:15377668 NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908
JBrowse link
G Src SRC proto-oncogene, non-receptor tyrosine kinase multiple interactions
decreases expression
ISO [Arsenic Trioxide co-treated with PD 173074] results in decreased expression of SRC protein; [Arsenic Trioxide results in increased susceptibility to PD 173074] which results in decreased expression of SRC protein; [PD 173074 results in increased susceptibility to Arsenic Trioxide] which results in decreased expression of SRC protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Arsenic Trioxide co-treated with PD 173074] results in decreased expression of SRC protein]; PD 173074 promotes the reaction [Arsenic Trioxide results in decreased expression of SRC protein modified form]; PD 173074 promotes the reaction [Arsenic Trioxide results in decreased expression of SRC protein]
PD 173074 results in decreased expression of SRC protein; PD 173074 results in decreased expression of SRC protein modified form
CTD PMID:27794399 NCBI chr 3:146,091,969...146,139,492
Ensembl chr 3:146,091,841...146,139,476
JBrowse link
G Tbx3 T-box transcription factor 3 multiple interactions ISO PD 173074 inhibits the reaction [afimoxifene results in increased expression of TBX3 protein]; PD 173074 inhibits the reaction [Estrogens results in increased expression of TBX3 protein] CTD PMID:21098263 NCBI chr12:36,879,924...36,894,849
Ensembl chr12:36,881,445...36,893,708
JBrowse link
G Vegfa vascular endothelial growth factor A multiple interactions ISO 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide promotes the reaction [PD 173074 inhibits the reaction [Sodium Chloride results in increased expression of VEGFA mRNA]]; PD 173074 inhibits the reaction [Sodium Chloride results in increased expression of VEGFA mRNA] CTD PMID:26800359 NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
JBrowse link

Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 19860
    role 19832
      biological role 19830
        biochemical role 19538
          apoptosis inducer 13657
            PD-166866 20
              PD173074 17
Path 2
Term Annotations click to browse term
  CHEBI ontology 19860
    subatomic particle 19858
      composite particle 19858
        hadron 19858
          baryon 19858
            nucleon 19858
              atomic nucleus 19858
                atom 19858
                  main group element atom 19804
                    p-block element atom 19804
                      carbon group element atom 19745
                        carbon atom 19741
                          organic molecular entity 19741
                            heteroorganic entity 19494
                              organochalcogen compound 19257
                                organooxygen compound 19173
                                  carbon oxoacid 18641
                                    carboxylic acid 18638
                                      carboacyl group 17705
                                        univalent carboacyl group 17705
                                          carbamoyl group 17556
                                            carboxamide 17556
                                              monocarboxylic acid amide 15688
                                                urea 5585
                                                  ureas 5583
                                                    PD-166866 20
                                                      PD173074 17
paths to the root